scholarly journals Predictors of Disease Progression in Mild Alzheimer’s Disease Dementia Patients – Results From the Geras Real World Cohort and Expedition Trials

2016 ◽  
Vol 19 (7) ◽  
pp. A425-A426
Author(s):  
C Reed ◽  
J Lebrec ◽  
JS Andrews ◽  
G Bruno ◽  
RW Jones
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Disease Progression ◽  
Real World ◽  
Dementia Patients ◽  
Alzheimer’S Disease Dementia

Institutional Respite Care: Benefits and Risks for Dementia Patients and Caregivers

1993 ◽  
Vol 5 (1) ◽  
pp. 67-77 ◽  
Author(s):  
Geri Adler ◽  
Linda Ott ◽  
Mary Jelinski ◽  
James Mortimer ◽  
Renee Christensen
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Behavior Problems ◽  
Activities Of Daily Living ◽  
Disease Progression ◽  
Daily Living ◽  
Respite Care ◽  
Dementia Patients ◽  
Before And After ◽  
Return Home

Thirty-seven dementia patients and their caregivers were studied before and after a two-week in-hospital respite stay. Institutional respite care did not alter behavior problems in dementia patients, nor did changes in performance of activities of daily living (ADLs) by Alzheimer's disease (AD) patients exceed those expected from disease progression. Caregivers exhibited an improvement in burden and depression during the respite study, but levels returned to baseline following the patient's return home.

Predictive value of ATN biomarker profiles in estimating disease progression in Alzheimer's disease dementia

2021 ◽  
Author(s):  
Ali Ezzati ◽  
Ahmed Abdulkadir ◽  
Clifford R. Jack ◽  
Paul M. Thompson ◽  
Danielle J. Harvey ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Disease Progression ◽  
Predictive Value ◽  
Alzheimer’S Disease Dementia

378 Use of a Clinician’s Global Impression of Severity scale to measure insomnia severity in Alzheimer’s disease-dementia patients

SLEEP ◽  
2021 ◽  
Vol 44 (Supplement_2) ◽  
pp. A150-A150
Author(s):  
Todd Saretsky ◽  
Paulette Ceesay ◽  
Wenjun Zhong ◽  
W Joseph Herring ◽  
Christopher Lines ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Real World ◽  
Pearson Correlation ◽  
Sleep Time ◽  
Response Category ◽  
Phase Iii ◽  
Controlled Clinical Trial ◽  
Dementia Patients ◽  
Insomnia Severity

Abstract Introduction Full montage polysomnography (PSG) is the gold standard for the objective evaluation of sleep but is time consuming and inaccessible to most clinicians. A Clinician’s Global Impression of Severity (CGI-S) scale can be used in clinical practice to provide a subjective assessment of patients’ insomnia severity. However, the utility of a CGI-S scale for assessing insomnia in patients with Alzheimer’s disease (AD)-dementia is not well understood. In a recent Phase III randomized, placebo-controlled clinical trial (NCT02750306), patients on suvorexant with AD-dementia and insomnia showed improvements in both PSG total sleep time (TST) and CGI-S scores. We conducted additional analyses to examine the association between CGI-S and PSG-TST to inform on the possible use of a CGI-S scale to assess insomnia severity in patients with AD-dementia in real-world settings. Methods Patients (N=285) met clinical diagnostic criteria for both probable mild-to-moderate AD-dementia and insomnia. The primary endpoint was change-from-baseline in overnight PSG-TST at Week-4. A single-item CGI-S rating of insomnia with responses of 1 (normal, not ill at all) to 7 (among the most extremely ill patients) was completed by a trained rater at baseline and after 2 and 4 weeks. CGI-S was an exploratory endpoint. Post-hoc correlational analyses and analyses of distribution of change-from-baseline to Week-4 in CGI-S response categories were performed. Results Pearson correlation indicated a significant association at baseline between PSG-TST and CGI-S (r=-0.18, nominal p=0.004). A correlation of change-from-baseline to Week-4 also indicated an association between PSG-TST and CGI-S (r=-0.24, nominal p<.0001). The distribution of change in CGI-S response category results at Week-4 showed that, compared to placebo, numerically less patients on suvorexant remained stable or worsened by >1 response category (21.8% vs. 29.4%, respectively) and numerically more improved by ≥1 response category (73.3% vs. 67.9%, respectively). Conclusion Our findings suggest that a CGI-S scale may be a useful tool for assessing insomnia severity in mild-to-moderate AD-dementia patients. Future studies with these patients are needed to determine the utility of a CGI-S scale in real-world settings. Support (if any) This study was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA

Sign in / Sign up

Export Citation Format

Share Document